• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Actym Therapeutics Appoints Chan Whiting as Chief Development Officer

    11/11/21 9:00:00 AM ET
    $QGEN
    $TPST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QGEN alert in real time by email

    BERKELEY, Calif., Nov. 11, 2021 /PRNewswire/ -- Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer. Chan brings over 20 years of drug development experience within the biotechnology industry. As CDO, Chan will play a key leadership role in advancing Actym's pipeline of first-in-class, systemically administered therapeutics that re-program the immunosuppressive microenvironment in solid tumors.  

    Actym Therapeutics Logo (PRNewsfoto/Actym Therapeutics, Inc.)

    Actym Therapeutics hires Dr. Chan Whiting as Chief Development Officer.

    "Chan has significant experience advancing novel cancer therapies into clinical development," said Christopher Thanos, Ph.D., Chief Executive Officer of Actym Therapeutics. "Her product development experience will be instrumental in guiding Actym as we prepare to become a clinical stage company over the coming months."

    "Actym's novel S. Typhimurium-Attenuated Cancer Therapy (STACT) therapies have the unique ability to bring immunogenic payloads to the tumor microenvironment to promote potent and durable anti-tumor responses to tackle difficult to treat cancers.  I look forward to joining the team and helping guide the development of this entirely novel class of immunotherapies."

    Chan was previously Senior Vice President and Head of Research and Development at Tempest Therapeutics (NASDAQ:TPST). Before joining Tempest, Chan was Head of Immune Monitoring and Biomarker Development at Aduro Biotech.  Prior to Aduro, she has held multiple scientific leadership positions at Ingenuity ((currently Qiagen, NYSE:QGEN) and Entelos, Inc.  Chan received her Ph.D. in Microbiology and Immunology at UCLA and completed her postdoctoral studies at Tularik, Inc. (currently Amgen) and Stanford University. 

    About Actym

    Actym Therapeutics, based in Berkeley, CA, is a privately-held biotechnology company focused on discovery and development of novel immuno-oncology therapies to treat cancer. The company has developed an attenuated, microbial-based, immunotherapeutic technology platform called STACT (S. Typhimurium-Attenuated Cancer Therapy). In preclinical studies, STACT specifically enriches in many types of solid tumors and not in healthy tissue. Once there, STACT delivers multiplexed immuno-modulatory payloads directly to tumor-resident immune cells. Many of these payload targets are of significant interest to the biopharmaceutical community but are intractable using conventional approaches due to systemic toxicities after intravenous dosing. Furthermore, STACT has been engineered to deliver payload combinations, which facilitates engagement of multiple biological pathways from a single therapy. In April of 2020, Actym raised $34 million in a Series A financing, co-led by Boehringer-Ingelheim Venture Fund and Panacea Venture Healthcare, with participation from Illumina Ventures, Korea Investment Partners, and JLO Ventures.

    Media Contact:

    Valerie Enes

    Seismic Media Relations

    [email protected]

    Corporate Contact:

    Sheriese Rush, MBA

    Head of Operations, Actym Therapeutics, Inc.

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/actym-therapeutics-appoints-chan-whiting-as-chief-development-officer-301421766.html

    SOURCE Actym Therapeutics Inc.

    Get the next $QGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QGEN
    $TPST

    CompanyDatePrice TargetRatingAnalyst
    Tempest Therapeutics Inc.
    $TPST
    4/10/2025Sector Outperform → Sector Perform
    Scotiabank
    Tempest Therapeutics Inc.
    $TPST
    4/10/2025Buy → Neutral
    H.C. Wainwright
    Qiagen N.V.
    $QGEN
    4/4/2025Buy → Neutral
    Redburn Atlantic
    Qiagen N.V.
    $QGEN
    2/19/2025$52.00 → $42.00Outperform → Neutral
    Robert W. Baird
    Qiagen N.V.
    $QGEN
    1/6/2025$48.00Overweight → Equal-Weight
    Morgan Stanley
    Qiagen N.V.
    $QGEN
    12/10/2024$42.50 → $54.00Hold → Buy
    Jefferies
    Qiagen N.V.
    $QGEN
    10/17/2024$49.00Buy → Hold
    HSBC Securities
    Qiagen N.V.
    $QGEN
    6/27/2024$50.00Peer Perform → Outperform
    Wolfe Research
    More analyst ratings

    $QGEN
    $TPST
    Leadership Updates

    Live Leadership Updates

    See more
    • Neogen Announces the Appointment of New Board Member

      LANSING, Mich., Oct. 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that it has appointed Thierry Bernard as a director to its Board, effective November 1, 2024. "We are pleased to welcome Thierry Bernard to the Neogen Board of Directors and look forward to his guidance as the company continues in its commitment to fueling a brighter future for global food security," said Jim Borel, Neogen's Board Chair. "As a sitting CEO with a wealth of knowledge in science and technologies relevant to Neogen and its

      10/1/24 8:45:00 AM ET
      $NEOG
      $QGEN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs

      BRISBANE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced the appointment of Sheldon Mullins as Vice President, Regulatory Affairs. Mr. Mullins' presence on the team builds upon the recent addition of Troy Wagner as Vice President of Quality Assurance, who brought additional late-stage experience to the company. Additionally, in connection with the plan to advance amezalpat into a pivotal study in first-line HCC patients and to reflect their roles in late-stage development, the titles of Darrin Bomba and Henry John

      9/18/24 8:00:00 AM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance

      BRISBANE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced the appointment of Troy M. Wagner as Vice President of Quality Assurance. "Troy brings a wealth of experience in late-stage product development, including managing quality systems across a range of global clinical studies and assisting with global regulatory filings. We look forward to her contributions as we move towards Phase 3 development of amezalpat to treat hepatocellular carcinoma and are thrilled to have her join the Tempest leadership team,"

      8/21/24 8:00:00 AM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QGEN
    $TPST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Qiagen N.V.

      SC 13G - QIAGEN N.V. (0001015820) (Subject)

      11/8/24 10:52:38 AM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Tempest Therapeutics Inc.

      SC 13D/A - Tempest Therapeutics, Inc. (0001544227) (Subject)

      8/12/24 8:59:00 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Tempest Therapeutics Inc. (Amendment)

      SC 13D/A - Tempest Therapeutics, Inc. (0001544227) (Subject)

      5/13/24 4:54:01 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QGEN
    $TPST
    SEC Filings

    See more
    • Amendment: SEC Form 10-K/A filed by Tempest Therapeutics Inc.

      10-K/A - Tempest Therapeutics, Inc. (0001544227) (Filer)

      4/30/25 4:05:19 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Tempest Therapeutics Inc.

      8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)

      4/28/25 9:49:42 AM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Tempest Therapeutics Inc.

      8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)

      4/18/25 4:16:40 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QGEN
    $TPST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Tempest Therapeutics downgraded by Scotiabank

      Scotiabank downgraded Tempest Therapeutics from Sector Outperform to Sector Perform

      4/10/25 8:50:49 AM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tempest Therapeutics downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Tempest Therapeutics from Buy to Neutral

      4/10/25 8:03:29 AM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Qiagen downgraded by Redburn Atlantic

      Redburn Atlantic downgraded Qiagen from Buy to Neutral

      4/4/25 8:39:19 AM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QGEN
    $TPST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • QIAGEN announces plans for transition in leadership of Supervisory Board

      Supervisory Board intends to elect Stephen H. Rusckowski as Chairman following Annual General Meeting on June 26, 2025 Lawrence A. Rosen will not stand for re-election and will step down as Chairman and Supervisory Board member following Annual General Meeting on June 26, 2025 Prof. Dr. Elaine Mardis will also not stand for re-election after serving since 2014 All other current Supervisory Board members will stand for re-election to one-year terms QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that its Supervisory Board intends to elect Stephen H. Rusckowski to succeed Lawrence A. Rosen as Chairman of the Supervisory Board following its Annual General Me

      5/7/25 4:20:00 PM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase

      Q1 2025 results confirm preliminary announcement: Net sales of $483 million (+5% actual rates, +7% constant exchange rates, CER); adjusted diluted EPS of $0.55 Net sales growth of +7% CER ahead of outlook for about +3% CER growth and adjusted diluted EPS of $0.56 CER ahead of outlook for at least $0.50 CER 29.8% adj. operating income margin up 4.1 percentage points vs. 25.7% in Q1 2024 Operating cash flow of $140 million in Q1 2025 vs. $133 million in Q1 2024 Proposal at Annual General Meeting to introduce a dividend as expansion of capital allocation strategy, also seek authorization for a new $500 million share repurchase Stephen H. Rusckowski proposed to become new Chairman

      5/7/25 4:05:00 PM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting

      QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that its Supervisory Board will propose the initiation of an annual cash dividend under an amended dividend policy to QIAGEN's shareholders at the next Annual General Meeting scheduled for June 26, 2025. This milestone reflects QIAGEN's strategy to introduce a new avenue to increase shareholder returns while preserving flexibility to reinvest in long-term growth. The Supervisory Board's decision on the amended dividend policy and initial dividend payment is subject to approval by QIAGEN's shareholders. The initial dividend payment would consist of $0.25 per ordinary share. This proposal represents a total payout of a

      5/7/25 8:45:00 AM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QGEN
    $TPST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by President and CEO Brady Stephen R

      4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

      1/6/25 5:00:25 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Maestas Nicholas

      4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

      1/6/25 5:00:20 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Corporate Controller Trojanowski Justin

      4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

      1/6/25 5:00:22 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QGEN
    $TPST
    Financials

    Live finance-specific insights

    See more
    • QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase

      Q1 2025 results confirm preliminary announcement: Net sales of $483 million (+5% actual rates, +7% constant exchange rates, CER); adjusted diluted EPS of $0.55 Net sales growth of +7% CER ahead of outlook for about +3% CER growth and adjusted diluted EPS of $0.56 CER ahead of outlook for at least $0.50 CER 29.8% adj. operating income margin up 4.1 percentage points vs. 25.7% in Q1 2024 Operating cash flow of $140 million in Q1 2025 vs. $133 million in Q1 2024 Proposal at Annual General Meeting to introduce a dividend as expansion of capital allocation strategy, also seek authorization for a new $500 million share repurchase Stephen H. Rusckowski proposed to become new Chairman

      5/7/25 4:05:00 PM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting

      QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that its Supervisory Board will propose the initiation of an annual cash dividend under an amended dividend policy to QIAGEN's shareholders at the next Annual General Meeting scheduled for June 26, 2025. This milestone reflects QIAGEN's strategy to introduce a new avenue to increase shareholder returns while preserving flexibility to reinvest in long-term growth. The Supervisory Board's decision on the amended dividend policy and initial dividend payment is subject to approval by QIAGEN's shareholders. The initial dividend payment would consist of $0.25 per ordinary share. This proposal represents a total payout of a

      5/7/25 8:45:00 AM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast

      QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2025. Press release date / time: Wednesday, May 7, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, May 8, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 828 8193 UK: +44 (0)330 165 3655 GER: +49 (0)69 6610 2480 Conference ID: 5803222 To avoid waiting time, please join the event conference 5-10 minute

      4/8/25 11:22:00 AM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QGEN
    $TPST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Brady Stephen R bought $73,850 worth of shares (35,000 units at $2.11), increasing direct ownership by 308% to 46,376 units (SEC Form 4)

      4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

      7/8/24 4:15:11 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Whiting Samuel bought $9,951 worth of shares (4,672 units at $2.13), increasing direct ownership by 95% to 9,573 units (SEC Form 4)

      4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

      7/3/24 7:35:42 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corporate Controller Trojanowski Justin bought $16,200 worth of shares (7,500 units at $2.16), increasing direct ownership by 51% to 22,168 units (SEC Form 4)

      4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

      7/2/24 4:15:14 PM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care